The operational outputs of the project allowed the in-country teams to fine-tune and strengthen their pricing assumptions for their asset’s incremental innovation
A country-needs assessment was added to the final report to aid the global team in the budget and resource allocation leading up to launch
Inbeeo’s client, a global specialty company, was actively preparing for the launch of a Long-Acting Injectable form of their block-buster short-acting oral equivalent. Inbeeo was tasked in helping them to operationalize their pricing strategy in Europe.
Payers usually poorly reward incremental innovation and the equivalence between long-acting and short-acting therapies is complex.
HOW WE APPROACHED THE CHALLENGE
Given the limited space to manoeuvre with the pricing strategy, we focused our efforts on the operational aspects of pricing, in a 2-step approach
The development of a Pricing Simulation tool
A series of workshops with affiliates teams to use the tool with a view to pressure-test their assumptions